ShRNA (short hairpin Ribonucleic Acid) of targeted silence BUB1B gene and application thereof
The invention belongs to the field of biological medicines, and particularly relates to shRNA for targeted silencing of a BUB1B gene and application of the shRNA. The shRNA molecule aiming at the BUB1B gene is designed and synthesized, an oligonucleotide sequence for constructing the shRNA is designed, and the molecule is combined with mRNA of the BUB1B gene to efficiently interfere post-transcription translation of the BUB1B gene and reduce expression of the BUB1B gene in lung cancer cells, so that proliferation and infiltration of the lung cancer cells are inhibited. The shRNA molecule has very important significance on anti-tumor treatment, is further developed into a clinical treatment drug, has huge potential value in research and development of anti-lung cancer target gene drugs in the future, and is expected to be applied to preparation of anti-tumor drugs with high efficiency, strong specificity and small side effects..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 04. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HE XIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-04, Last update posted on www.tib.eu: 2023-11-28, Last updated: 2023-12-01 |
|---|
| Patentnummer: |
CN116376912 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018232655 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018232655 | ||
| 003 | DE-627 | ||
| 005 | 20231201095022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231013s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018232655 | ||
| 035 | |a (EPA)CN116376912 | ||
| 035 | |a (EPA)86973951 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HE XIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ShRNA (short hairpin Ribonucleic Acid) of targeted silence BUB1B gene and application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-04, Last update posted on www.tib.eu: 2023-11-28, Last updated: 2023-12-01 | ||
| 520 | |a The invention belongs to the field of biological medicines, and particularly relates to shRNA for targeted silencing of a BUB1B gene and application of the shRNA. The shRNA molecule aiming at the BUB1B gene is designed and synthesized, an oligonucleotide sequence for constructing the shRNA is designed, and the molecule is combined with mRNA of the BUB1B gene to efficiently interfere post-transcription translation of the BUB1B gene and reduce expression of the BUB1B gene in lung cancer cells, so that proliferation and infiltration of the lung cancer cells are inhibited. The shRNA molecule has very important significance on anti-tumor treatment, is further developed into a clinical treatment drug, has huge potential value in research and development of anti-lung cancer target gene drugs in the future, and is expected to be applied to preparation of anti-tumor drugs with high efficiency, strong specificity and small side effects. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHEN SHENGJIE |4 aut | |
| 700 | 0 | |a SHANG DONGSHENG |4 aut | |
| 700 | 0 | |a LIU HANQING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 04. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:04 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86973951/publication/CN116376912A1?q=CN116376912 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 04 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 04 |c 07 | ||